secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003933
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback
--------------------------------------------------------------------------------

- Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.
- 2024 revenue guidance $600-630 million; cash and investments $425.4M at Dec 31, 2023.
- Board authorized $200M stock repurchase program; effective Jan 10, 2024.
- Results are preliminary, unaudited, and subject to audit adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/d45395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer